Department of Neurology, Semmelweis University, Balassa utca 6., H-1083, Budapest, Hungary.
MTA-SE, Neuroepidemiological Research Group ELKH, Balassa utca 6., H-1083, Budapest, Hungary.
Geroscience. 2022 Feb;44(1):253-263. doi: 10.1007/s11357-021-00470-7. Epub 2021 Oct 15.
Dementia is one of the leading causes of death and disability in older population. Previous reports have shown that antidementia medications are associated with longer survival; nonetheless, the prevalence of their use and the compliance with them are quite different worldwide. There is hardly any available information about the pharmacoepidemiology of these drugs in the Eastern-European region; we aimed to analyze the use of cholinesterase inhibitors (ChEis) for the treatment of dementia to provide real-life information from the Eastern European region. All medical and medication prescription reports of the in- and outpatient specialist services collected in the NEUROHUN database in Hungary were analyzed between 2013 and 2016. Survival, adherence, and persistence values were calculated. 8803 patients were treated with ChEis during the study period, which was only 14.5% of the diagnosed demented patients. The survival of treated patients (more than 4 years) was significantly longer than patients without ChEi treatment (2.50 years). The best compliance was observed with rivastigmine patch. Choosing the appropriate medication as soon as possible after the dementia diagnosis may lead to increased life expectancy.
痴呆症是老年人群中导致死亡和残疾的主要原因之一。先前的报告表明，抗痴呆症药物与延长生存时间有关；然而，它们的使用的普遍性和依从性在世界范围内存在很大差异。东欧地区几乎没有关于这些药物的药物流行病学的信息；我们旨在分析胆碱酯酶抑制剂（ChEis）在治疗痴呆症中的使用情况，以提供来自东欧地区的真实信息。在匈牙利的 NEUROHUN 数据库中收集了 2013 年至 2016 年的门诊和住院专家服务的所有医疗和药物处方报告，并对其进行了分析。计算了生存、依从性和持久性值。在研究期间，有 8803 名患者接受了 ChEis 治疗，仅占确诊痴呆患者的 14.5%。接受治疗的患者（超过 4 年）的生存时间明显长于未接受 ChEi 治疗的患者（2.50 年）。使用 rivastigmine 贴片的依从性最好。在痴呆症诊断后尽快选择合适的药物可能会延长预期寿命。
